Prostate Cancer Risk, Screening, and Management in Patients with Germline BRCA1/2 Mutations

Several prospective studies of prostate cancer incidence and screening among BRCA1/2 mutation carriers have indicated at least a twofold to fourfold increase in prostate cancer risk among carriers of BRCA2 mutations compared with the general population.